Evidence map›Paper›PMID 32079701›Full record

ArticleHaematologica2021

Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas.

Sabela Bobillo, Marta Crespo, Laura Escudero, Regina Mayor, Priyanka Raheja, Cecilia Carpio, Carlota Rubio-Perez, Bárbara Tazón-Vega, Carlos Palacio, Júlia Carabia and 10 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  4. Article
  5. Review
  6. Review
  7. Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Sabela BobilloVall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Marta CrespoVall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Laura EscuderoTranslational Research Program, Vall Hebron Institute of Oncology (VHIO).
Regina MayorTranslational Research Program, Vall Hebron Institute of Oncology (VHIO).
Priyanka RahejaVall Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Cecilia CarpioVall Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Carlota Rubio-PerezTranslational Research Program, Vall Hebron Institute of Oncology (VHIO).
Bárbara Tazón-VegaVall Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Carlos PalacioVall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Júlia CarabiaVall Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Isabel JiménezVall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Juan C NietoVall Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Julia MontoroVall Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Francisco Martínez-RicarteDepartment of Neurosurgery, Hospital Vall d'Hebron.
Josep CastellviDepartment of Pathology, Hospital Vall Hebron.
Marc SimóDepartment of Nuclear Medicine, Vall Hebron University Hospital.
Lluis PuigdefàbregasVall Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Pau AbrisquetaVall Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Francesc BoschVall Hebron University Hospital, Universitat Autònoma de Barcelona, Department of Medicine.
Joan SeoaneTranslational Research Program, Vall Hebron Institute of Oncology (VHIO).
Hebron University · PSUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The levels of cell free circulating tumor DNA (ctDNA) in plasma correlated with treatment response and outcome in systemic lymphomas. Notably, in brain tumors, the levels of ctDNA in the cerebrospinal fluid (CSF) are higher than in plasma. Nevertheless, their role in central nervous system (CNS) lymphomas remains elusive. We evaluated the CSF and plasma from 19 patients: 6 restricted CNS lymphomas, 1 systemic and CNS lymphoma, and 12 systemic lymphomas. We performed whole exome sequencing or targeted sequencing to identify somatic mutations of the primary tumor, then variant-specific droplet digital PCR was designed for each mutation. At time of enrolment, we found ctDNA in the CSF of all patients with restricted CNS lymphoma but not in patients with systemic lymphoma without CNS involvement. Conversely, plasma ctDNA was detected in only 2/6 patients with restricted CNS lymphoma with lower variant allele frequencies than CSF ctDNA. Moreover, we detected CSF ctDNA in 1 patient with CNS lymphoma in complete remission and in 1 patient with systemic lymphoma, 3 and 8 months before CNS relapse was confirmed; indicating CSF ctDNA might detect CNS relapse earlier than conventional methods. Finally, in 2 cases with CNS lymphoma, CSF ctDNA was still detected after treatment even though a complete decrease in CSF tumor cells was observed by flow cytometry (FC), indicating CSF ctDNA better detected residual disease than FC. In conclusion, CSF ctDNA can better detect CNS lesions than plasma ctDNA and FC. In addition, CSF ctDNA predicted CNS relapse in CNS and systemic lymphomas.

Indexed as

Circulating Tumor DNALymphoma, B-CellBiomarkers, TumorCentral Nervous SystemHumansNeoplasm Recurrence, LocalBiomarkers, TumorCirculating Tumor DNA

Identifiers

PMID32079701
PMCPMC7849551
OpenAlexW3008151329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.